mediworkAI Secures Funding From Korea Investment Accelerator to Expand From Data Annotation Into Clinical AI Validation

mediworkAI, a Korean medical AI data and validation startup built on a network of specialist physicians, has secured funding after being selected for Korea Investment Accelerator‘s Bareun Donghaeng accelerating program.

Drawing on a network of more than 1,200 specialist physicians across 25 medical departments, mediworkAI operates what it calls a “medical AI MLOps” business, collecting and processing the data medical AI developers need while verifying and improving the clinical reliability of their models. High-quality data generated and validated directly by specialist doctors is essential for medical AI, yet the industry has long faced a structural bottleneck: a shortage of expert data providers and clinical validation partners, along with limited access to physician networks.

The company’s service spans three stages. It starts with annotation, where specialist physicians process medical data directly. It moves into evaluation, where physicians assess and refine AI-generated responses. It concludes with clinical validation, where an independent panel of specialists blind-tests a model’s clinical performance and issues a report under their own names. That third stage, clinical validation, doubles as supporting documentation for regulatory approval from Korea’s Ministry of Food and Drug Safety and the US FDA, yet there are few, if any, providers in Korea equipped to handle it as an outsourced service — precisely the gap mediworkAI is targeting.

Regulatory changes are also working in the company’s favor. Korea’s Digital Medical Products Act, which took effect last year, introduced a Predetermined Change Control Plan system requiring AI models to be revalidated each time they are updated. That shift turns clinical validation from a one-off project into a recurring compliance need, structurally widening the market mediworkAI serves.

mediworkAI was founded by a chief executive who previously led DoctorWorks, a medical AI subsidiary of KOSDAQ-listed AI data company CrowdWorks, and who has held senior roles across healthcare, pharmaceutical and AI businesses, alongside a chief medical officer who is a board-certified internal medicine specialist. The company draws on medical expertise and data-business know-how from Aseptic Asia, an investment firm founded by specialist physicians, as well as sales network support from CrowdWorks.

A representative of Korea Investment Accelerator, which led the investment, said medical AI is difficult to build without physician-generated data and independent clinical validation, and that mediworkAI stands out for combining a specialist network spanning every medical department with clinical validation capabilities rarely found in Korea. The representative added that as tighter regulation structurally increases demand for validation, the firm expects mediworkAI to help close that gap.

“Building on this selection, we plan to expand beyond medical data annotation into AI model evaluation and clinical validation, while preparing to enter global markets including Asia,” said mediworkAI chief executive Seung-gyu Yoon. “We aim to establish ourselves as an AI infrastructure company that connects medical AI development with clinical practice.”